Antimicrobial susceptibilities of Proteus mirabilis: A longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Wang, Jann Tay ^a,b   Chen, Pei Chen ^b   Chang, Shan Chwen ^a,c   Shiau, Yih Ru ^b   Wang, Hui Ying ^b   Lai, Jui Fen ^b   Huang, I Wen ^b   Tan, Mei Chen ^b   Lauderdale, Tsai Ling Yang ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

AmpC lactamase; Clinical and Laboratory Standards Institute (CLSI); Drug resistance; Extended spectrum lactamase; Proteus mirabilis

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CMY; BETA LACTAMASE CTX M; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN; UNCLASSIFIED DRUG; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; ENZYME SYNTHESIS; GENE IDENTIFICATION; HOSPITAL PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT; POLYMERASE CHAIN REACTION; PREDICTION; PREVALENCE; PROTEUS MIRABILIS; TAIWAN; URINARY TRACT INFECTION; YOUNG ADULT; CHILD; DRUG EFFECTS; FEMALE; GENETICS; HEALTH SURVEY; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PRESCHOOL CHILD; PROTEUS INFECTIONS; URINARY TRACT INFECTIONS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZTREONAM; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; CEFOTAXIME; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; TAIWAN; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84906929482     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-486     Document Type: Article

References (36)

1. Mobley HL, Belas R. Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Trends Microbiol 1995, 3:280-284. 10.1016/S0966-842X(00)88945-3, 7551643.
2. Rozalski A, Sidorczyk Z, Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 1997, 61:65-89. 232601, 9106365.
3. Warren JW, Tenney JH, Hoopes JM, Muncie HL, Anthony WC. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 1982, 146:719-723. 10.1093/infdis/146.6.719, 6815281.
4. Kunin CM. Blockage of urinary catheters: role of microorganisms and constituents of the urine on formation of encrustations. J Clin Epidemiol 1989, 42:835-842. 10.1016/0895-4356(89)90096-6, 2778465.
5. Chanal C, Bonnet R, De Champs C, Sirot D, Labia R, Sirot J. Prevalence of β-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob Agents Chemother 2000, 44:1930-1935. 10.1128/AAC.44.7.1930-1935.2000, 89988, 10858357.
6. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010, 54:969-976. 10.1128/AAC.01009-09, 2825993, 19995920.
7. D'Andrea MM, Literacka E, Zioga A, Giani T, Baraniak A, Fiett J, Sadowy E, Tassios PT, Rossolini GM, Gniadkowski M, Miriagou V. Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type cephalosporinases in Europe. Antimicrob Agents Chemother 2011, 55:2735-2742. 10.1128/AAC.01736-10, 3101460, 21402851.
8. Nakano R, Nakano A, Abe M, Inoue M, Okamoto R. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan. J Med Microbiol 2012, 61:1727-1735. 10.1099/jmm.0.049726-0, 22935848.
9. Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob Agents Chemother 2005, 49:2598-2605. 10.1128/AAC.49.7.2598-2605.2005, 1168714, 15980325.
10. Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 2010, 13:558-564. 10.1016/j.mib.2010.09.006, 20920882.
11. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798. 10.3201/eid1710.110655, 3310682, 22000347.
12. Horner CS, Abberley N, Denton M, Wilcox MH. Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010-2012. Epidemiol Infect 2014, 142:399-403. 10.1017/S0950268813000988, 23657157.
13. Miro E, Aguero J, Larrosa MN, Fernandez A, Conejo MC, Bou G, Gonzalez-Lopez JJ, Lara N, Martinez-Martinez L, Oliver A, Aracil B, Oteo J, Pascual A, Rodriguez-Bano J, Zamorano L, Navarro F. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 2013, 32:253-259. 10.1007/s10096-012-1737-0, 22956023.
14. Sheng WH, Badal RE, Hsueh PR. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013, 57:2981-2988. 10.1128/AAC.00971-12, 3697370, 23587958.
15. Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2011. Clin Ther 2013, 35:872-877. 10.1016/j.clinthera.2013.03.022, 23623624.
16. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA. Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. J Infect 2014, 68:71-76. 10.1016/j.jinf.2013.09.001, 24016768.
17. Karlowsky JA, Adam HJ, Baxter MR, Lagace-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother 2013, 57:5600-5611. 10.1128/AAC.01485-13, 3811279, 23979759.
18. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis 2014, 78:443-448. 10.1016/j.diagmicrobio.2013.11.025, 24492025.
19. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fourth Informational Supplement. M100-S24. Clinical and Laboratory Standards Institute 2014, Wayne, PA: CLSI, Document M100-S24, Clinical and Laboratory Standards Institute.
20. Villar HE, Danel F, Livermore DM. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other β-lactams. J Antimicrob Chemother 1997, 40:365-370. 10.1093/jac/40.3.365, 9338488.
21. Jean SS, Hsueh PR, Lee WS, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Lam C, Chen RJ. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. Int J Antimicrob Agents 2013, 41:457-462. 10.1016/j.ijantimicag.2013.02.001, 23507415.
22. Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. J Microbiol Immunol Infect 2004, 37:185-191.
23. Kuo SC, Chang SC, Wang HY, Lai JF, Chen PC, Shiau YR, Huang IW, Lauderdale TL. Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect Dis 2012, 12:200. 10.1186/1471-2334-12-200, 3462144, 22929085.
24. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility tests for Bacteria That Grow Aerobically; Approved Standard-Ninth Edition. CLSI documents M07-A09. Clinical and Laboratory Standards Institute 2012, Wayne, PA, USA: CLSI, Clinical and Laboratory Standards Institute.
25. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. Nineteenth Informational Supplement. M100-S19. Clinical and Laboratory Standards Institute (CLSI) 2009, Wayne, PA: CLSI, Document M100-S19, Clinical and Laboratory Standards Institute.
26. Monstein HJ, Ostholm-Balkhed A, Nilsson MV, Nilsson M, Dornbusch K, Nilsson LE. Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX-M genes in Enterobacteriaceae. APMIS 2007, 115:1400-1408. 10.1111/j.1600-0463.2007.00722.x, 18184411.
27. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002, 40:2153-2162. 10.1128/JCM.40.6.2153-2162.2002, 130804, 12037080.
28. O'Brien TF, Stelling J. Integrated multilevel surveillance of the world's infecting microbes and their resistance to antimicrobial agents. Clin Microbiol Rev 2011, 24:281-295. 10.1128/CMR.00021-10, 3122493, 21482726.
29. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. Census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 2014, 58:833-838. 10.1128/AAC.01896-13, 3910895, 24247134.
30. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, Chang FY, Chang SC. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 2012, 7:e37788. 10.1371/journal.pone.0037788, 3357347, 22629456.
31. European Committee on Antimicrobial Susceptibility Testing MIC distributions. 2012, http://www.eucast.org/mic_distributions/[Accessed01.04.14], European Committee on Antimicrobial Susceptibility Testing.
32. Centers for Diseases Control and Prevention The CDC guidance for control of CRE-2012 CRE toolkit. Available from http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-08.pdf, Centers for Diseases Control and Prevention.
33. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis 2013, 56:1301-1309. 10.1093/cid/cit017, 23334813.
34. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART global surveillance study. Int J Antimicrob Agents 2010, 36:293-294. 10.1016/j.ijantimicag.2010.05.012, 20598511.
35. Tan TY, Ng LS, He J, Chen DM. Improved detection of AmpC β-lactamases in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis using new susceptibility breakpoints for third-generation cephalosporins. Diagn Microbiol Infect Dis 2011, 70:423-424. 10.1016/j.diagmicrobio.2011.03.008, 21549542.
36. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum β-lactamases. Clin Microbiol Infect 2008, 14(Suppl 1):33-41.